6-methyl-2-methylquinolin-3-amine | 39583-00-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 6-methyl-2-methylquinolin-3-amine
• 英文别名: 2,6-dimethylquinolin-3-amine；2,6-Dimethyl-3-quinolinamine
• CAS: 39583-00-1
• 化学式: C₁₁H₁₂N₂
• 分子量: 172.23
• InChiKey: JZICXALTAFJCCU-UHFFFAOYSA-N

物化性质

• 沸点：
  324.7±37.0 °C(Predicted)
• 密度：
  1.136±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  38.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-氨基-5-甲基苯甲酸 在 manganese(IV) oxide 、 lithium aluminium tetrahydride 、 三苯基膦氯金 、 silver trifluoromethanesulfonate 作用下， 以 四氢呋喃 、 二氯甲烷 、 乙腈 为溶剂， 反应 28.0h， 生成 6-methyl-2-methylquinolin-3-amine
  参考文献：
  名称：

  2–氨基苯甲醛与炔丙基胺之间的金（I）催化的前所未有的重排反应：通往3–氨基喹啉的便捷途径

  摘要：

  接触氨基喹啉：研究了2-氨基苯甲醛与炔丙基胺之间的金（I）催化的前所未有的重排反应。该研究首次从容易获得的起始原料开始，一步就可以直接获得3-氨基喹啉（见方案）。精心设计的实验用于阐明这种前所未有的重排的机制，这一点已通过DFT计算得到了证实。

  DOI：

  10.1002/chem.201103668

文献信息

• [EN] INHIBITORS OF TRKA KINASE<br/>[FR] INHIBITEURS DE TRKA KINASE
  申请人：GVK BIOSCIENCES PRIVATE LTD

  公开号：WO2016116900A1

  公开（公告）日：2016-07-28

  The present invention is directed to the compounds of Formula I which are inhibitors of tropomyosin-related kinase A (TrkA): Formula (I) or steroisomers, tautomers or a pharmaceutically acceptable salts, metabolites, isotopes, solvates or prodrugs thereof, wherein, Ra, Rb, Rc, Rd, R1, R2, L and Het-Ar are as defined herein. These compounds can be used for the preventive and/or therapeutic treatment of diseases or disorders associated with abnormal activities of nerve growth factor (NGF) receptor TrkA such as Pain, inflammation or an inflammatory diseases, Cancer, atherosclerosis, restenosis, thrombosis, Neurodegenerative diseases, Erectile Dysfunction (ED), Skin disorders, Autoimmune disease like Multiple sclerosis, Sjögren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis, Infectious diseases, diseases related to an imbalance of the regulation of bone remodeling, endometriosis, pelvic pain syndrome and diseases resulting from abnormal tissue remodelling and fibrotic disorders; or a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination.

  本发明涉及式I的化合物，该化合物是Tropomyosin-related kinase A（TrkA）的抑制剂：式（I）或其立体异构体、互变异构体或药学上可接受的盐、代谢物、同位素、溶剂合物或前药，其中，Ra、Rb、Rc、Rd、R1、R2、L和Het-Ar如本文所定义。这些化合物可用于预防和/或治疗与神经生长因子（NGF）受体TrkA的异常活动相关的疾病或障碍，如疼痛、炎症或炎症性疾病、癌症、动脉粥样硬化、再狭窄、血栓形成、神经退行性疾病、勃起功能障碍（ED）、皮肤疾病、多发性硬化、干燥综合征、子宫内膜异位症、糖尿病周围神经病变、前列腺炎、传染病、与骨重塑调节失衡相关的疾病、子宫内膜异位症、盆腔疼痛综合征以及由异常组织重塑和纤维化疾病引起的疾病；或与失髓鞘形成或脱髓鞘相关的疾病、障碍、损伤或功能障碍。
• Inhibitors of TrkA kinase
  申请人：GVK BIOSCIENCES PRIVATE LIMITED

  公开号：US10336723B2

  公开（公告）日：2019-07-02

  The present invention is directed to the compounds of Formula I which are inhibitors of tropomyosin-related kinase A (TrkA): Formula (I) or stereoisomers, tautomers or a pharmaceutically acceptable salts, metabolites, isotopes, solvates or prodrugs thereof, wherein, Ra, Rb, Rc, Rd, R1, R2, L and Het-Ar are as defined herein. These compounds can be used for the preventive and/or therapeutic treatment of diseases or disorders associated with abnormal activities of nerve growth factor (NGF) receptor TrkA such as Pain, inflammation or an inflammatory diseases, Cancer, atherosclerosis, restenosis, thrombosis, Neurodegenerative diseases, Erectile Dysfunction (ED), Skin disorders, Autoimmune disease like Multiple sclerosis, Sjögren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis, Infectious diseases, diseases related to an imbalance of the regulation of bone remodeling, endometriosis, pelvic pain syndrome and diseases resulting from abnormal tissue remodelling and fibrotic disorders; or a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination.

  本发明涉及式 I 的化合物，它们是肌球蛋白相关激酶 A（TrkA）的抑制剂：式(I)或其立体异构体、同分异构体或药学上可接受的盐、代谢物、同位素、溶媒或原药，其中，Ra、Rb、Rc、Rd、R1、R2、L 和 Het-Ar 如本文所定义。这些化合物可用于预防和/或治疗与神经生长因子（NGF）受体 TrkA 的异常活动有关的疾病或紊乱，如疼痛、炎症或炎症性疾病、癌症、动脉粥样硬化、血管再狭窄、血栓形成、神经退行性疾病、勃起功能障碍（ED）、皮肤病、自身免疫性疾病（如多发性硬化症、斯约格伦综合征）、子宫内膜异位症、糖尿病周围神经病变、前列腺炎、传染病、与骨重塑调节失衡有关的疾病、子宫内膜异位症、盆腔疼痛综合征以及由异常组织重塑和纤维化紊乱引起的疾病；或与髓鞘脱落或脱髓鞘有关的疾病、失调、损伤或功能障碍。
• INHIBITORS OF TRKA KINASE
  申请人：GVK Biosciences Private Limited

  公开号：EP3247692A1

  公开（公告）日：2017-11-29
• Gold(I)-Catalyzed Unprecedented Rearrangement Reaction Between 2-Aminobenzaldehydes with Propargyl Amines: An Expedient Route to 3-Aminoquinolines
  作者：Nitin T. Patil、Vivek S. Raut、Valmik S. Shinde、Gaddamanugu Gayatri、G. Narahari Sastry

  DOI：10.1002/chem.201103668

  日期：2012.4.27

  aminoquinolines: A gold(I)‐catalyzed unprecedented rearrangement reaction between 2‐aminobenzaldehydes with propargyl amine was studied. The study provided, for the first time, direct access to 3‐aminoquinolines in one step starting from readily available starting materials (see scheme). Elegantly designed experiments were employed to unravel the mechanism of this unprecedented rearrangement, which are corroborated

  接触氨基喹啉：研究了2-氨基苯甲醛与炔丙基胺之间的金（I）催化的前所未有的重排反应。该研究首次从容易获得的起始原料开始，一步就可以直接获得3-氨基喹啉（见方案）。精心设计的实验用于阐明这种前所未有的重排的机制，这一点已通过DFT计算得到了证实。